# Cetuximab Combined With Pembrolizumab or Finotonlimab and Chemotherapy in R/M HNSCC

> **NCT07509099** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Ji Dongmei** · enrollment: 316 (estimated)

## Conditions studied

- Squamous Cell Carcinoma of Head and Neck

## Interventions

- **DRUG:** cetuximab+PD-1 mAb(Pembrolizumab/Finotonlimab)+chemotherapy
- **DRUG:** PD-1 mAb (Pembrolizumab/Finotonlimab) + chemothearpy

## Key facts

- **NCT ID:** NCT07509099
- **Lead sponsor:** Ji Dongmei
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04-01
- **Primary completion:** 2030-09-30
- **Final completion:** 2030-09-30
- **Target enrollment:** 316 (ESTIMATED)
- **Last updated:** 2026-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07509099

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07509099, "Cetuximab Combined With Pembrolizumab or Finotonlimab and Chemotherapy in R/M HNSCC". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07509099. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*